Paul Tudor Jones Xenon Pharmaceuticals Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 25,157 shares of XENE stock, worth $980,871. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,157
Previous 43,221
41.79%
Holding current value
$980,871
Previous $1.99 Million
45.58%
% of portfolio
0.01%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding XENE
# of Institutions
227Shares Held
69MCall Options Held
307KPut Options Held
68.9K-
Avoro Capital Advisors LLC New York, NY5.67MShares$221 Million2.94% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.32MShares$169 Million2.04% of portfolio
-
Wellington Management Group LLP Boston, MA3.92MShares$153 Million0.03% of portfolio
-
Capital World Investors Los Angeles, CA2.68MShares$105 Million0.02% of portfolio
-
Polar Capital Holdings PLC London, X02.61MShares$102 Million0.7% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.43B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...